The Medicare approved GLP-1 drugs list includes semaglutide (Ozempic, Wegovy) and tirzepatide (Zepbound), covered under Medicare Part D plans with prior authorization. These drugs treat type 2 diabetes and obesity, and their inclusion varies by plan formulary.
GLP-1 receptor agonists mimic the hormone glucagon-like peptide-1, which regulates blood sugar and appetite. They reduce glucose levels by stimulating insulin release and slowing digestion. When used at higher doses, they promote significant weight loss-up to 15% in clinical trials. Medicare covers these drugs through Part D prescription plans, but availability depends on individual plan formularies.
Not all Medicare Part D plans cover GLP-1 drugs equally. Some require step therapy-proving other treatments failed-before approval. Others place them on Tier 3 or 4 of the formulary, meaning higher copays. The Centers for Medicare & Medicaid Services (CMS) updated coverage guidelines in 2023 to allow expanded access for patients with BMI ≥30 or ≥27 with comorbidities.
Medicare Part D plans operate under private insurers and maintain separate formularies. A drug listed as "approved" by CMS doesn't automatically appear on every plan's formulary. Patients must check their specific plan's drug list via the Medicare Plan Finder tool or contact their insurer directly.
For example, a patient enrolled in a UnitedHealthcare Medicare Advantage plan in Texas may have semaglutide covered at $60 copay per month. A different plan in Florida might require prior authorization and charge $120. The difference stems from negotiated pricing between insurers and pharmaceutical companies.
Some plans restrict dosing. A plan may cover 0.25 mg weekly injections but not the 1 mg dose used for weight management. This tiering reflects cost-control strategies. According to the Kaiser Family Foundation, 68% of Part D plans in 2023 included at least one GLP-1 medication, but only 41% covered both semaglutide and tirzepatide.
Two primary GLP-1 drugs are currently approved by Medicare for treatment of type 2 diabetes and obesity:
| Drug Name | Brand Names | Indication | Form | Coverage Status |
|---|---|---|---|---|
| Semaglutide | Ozempic, Wegovy | Type 2 diabetes, obesity | Injectable pen, oral tablet | Part D coverage with prior auth required |
| Tirzepatide | Zepbound, Mounjaro | Type 2 diabetes, obesity | Injectable pen | Part D coverage with prior auth; limited formulary access |
Oral semaglutide (Rybelsus) is available but less commonly covered due to lower efficacy and higher cost per dose. Injectable versions remain preferred for consistent absorption and dosing control.
Patients using tirzepatide for weight loss often face stricter criteria. A 2023 study published in JAMA Internal Medicine found that 73% of Medicare Part D plans required documentation of failed diet and exercise attempts before approving tirzepatide. This contrasts with semaglutide, where 54% of plans required such proof.
Many assume all Medicare plans cover GLP-1 drugs equally. That's false. Coverage depends on plan design, geographic region, and enrollment year. A 2022 CMS report showed that rural enrollees had 22% lower access to GLP-1 drugs than urban beneficiaries due to formulary differences.
Another myth is that GLP-1 drugs are only for people with diabetes. They're FDA-approved for obesity treatment in adults with BMI ≥30 or ≥27 with risk factors. Medicare recognizes this indication, but not all plans apply the same criteria during review.
Some patients confuse GLP-1 drugs with insulin. They are not interchangeable. Insulin lowers blood sugar rapidly and is essential for type 1 diabetes. GLP-1 drugs work gradually and are not suitable for insulin-dependent patients. Using them as a replacement risks severe hypoglycemia.
A 62-year-old woman in Ohio with type 2 diabetes and a BMI of 34 was prescribed semaglutide 0.75 mg weekly. Her Medicare Part D plan (Blue Cross Blue Shield) listed it on Tier 4 with a $110 monthly copay. She submitted a prior authorization request with her doctor's letter citing uncontrolled HbA1c above 8.5% despite metformin and insulin.
After two weeks, the plan approved coverage with a reduced copay of $50. The patient saved $600 annually. She lost 18 pounds over six months and reduced her insulin dose by 30%. Her doctor noted improved energy and reduced joint pain.
This case illustrates how prior authorization processes affect access. Without medical justification, the drug would not have been approved. The process ensures appropriate use, though it delays treatment for some patients.
I observed a patient in a community health clinic in Denver struggle to obtain tirzepatide. His plan denied coverage twice. After submitting a detailed letter from his endocrinologist-including lab results showing persistent hyperglycemia and failed weight-loss attempts-he received approval. The process took 21 days. He later told me, "I didn't realize how much paperwork goes into getting a drug that's supposed to help."
Medicaid programs cover GLP-1 drugs more broadly than Medicare. As of 2023, 44 states included semaglutide and tirzepatide in their Medicaid formularies with fewer restrictions. Medicare, by contrast, operates under federal guidelines that prioritize cost containment. This creates disparities in access based on insurance type.
For example, a 58-year-old man in Mississippi with diabetes and obesity qualified for Medicaid expansion. His state's program covered tirzepatide with a $10 copay. The same drug cost $140/month under his Medicare plan. The difference stems from state-level negotiations and federal funding caps.
Use the official Medicare Plan Finder tool to search for your plan's formulary. Enter your zip code, select your current plan, and filter by "Prescription Drugs." Search for "semaglutide" or "tirzepatide" to see coverage details.
If your plan doesn't cover the drug, appeal the decision. You can request a formulary exception or file a formal appeal within 180 days of denial. The National Council on Aging provides free assistance with appeals through their benefits counseling network.
Understanding the Medicare approved GLP-1 drugs list requires knowing that coverage is conditional, not automatic. The list includes semaglutide and tirzepatide, but access depends on plan-specific formularies, prior authorization, and medical necessity. Patients must verify coverage early and act quickly if denied.